Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells + human umbilical cord-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Chaitanya Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a combination cell therapy consisting of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) and allogeneic human umbilical cord-derived mesenchymal stem cells (UC-MSCs). Developed by Chaitanya Hospital in Pune, India, this therapy is being evaluated for the treatment of liver cirrhosis. Mesenchymal stem cells are multipotent stromal cells that possess immunomodulatory, anti-inflammatory, and pro-regenerative properties. In the context of liver cirrhosis, these cells are hypothesized to reduce hepatic fibrosis, promote hepatocyte regeneration, and improve liver function by secreting various cytokines and growth factors. The treatment involves intravenous administration of the cells in divided doses.
- Other names
- Mesenchymal stem cellStem Cells for Liver Cirrhosishuman umbilical cord-derived mesenchymal stem cells-Chaitanya Hospital, Pune-liver cirrhosis
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells + human umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells + human umbilical cord-derived mesenchymal stem cells.